



an Open Access Journal by MDPI

Multigene Assays in Early Breast Cancer: Implications for Classification, Staging, Prognosis and Treatment

Guest Editors:

Dr. Alberto Zambelli

Medical Oncology Unit, Azienda
Ospedaliera Papa Giovanni XXIII,
24127 Bergamo, Italy

Dr. Carlo Tondini

Azienda Ospedaliera Papa
Giovanni XXIII, Bergamo, Italy

Deadline for manuscript
submissions:
closed (31 October 2021)

Message from the Guest Editors

In the last 2 decade, a new conceptual approach to breast cancer (BC) has emerged, providing a better understanding of the biology of the disease. With the advent of genomic analyses, it has become evident the BC is not a single type of tumor, but a group of different diseases with distinct molecular properties, eventually defined by the use of multigene assays (MGAs). Each of these different molecular properties identify different BC subtypes that tend to respond differently to the anti-cancer therapy. This fuelled the promise of MGAs to provide detailed and specific molecular information, which will ultimately lead to individualize a more precise BC treatment, along with a more accurate BC classification and staging.

This Special Issue focuses on the role and impact of the different MGAs in eBC and their implications for classification, staging, prognosis and treatment. We cordially invite authors in the field to submit original research or review articles pertaining to this important and progressing field of biomedicine.



mdpi.com/si/62089

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI